19 March 2007: On 16 March 2007 Barracuda Invest subscribed for 46,155 shares, START-fondet ASA for 2,979,511 shares, Biovekst AS for 1,754,842 shares, Anders Holmberg for 734,655 shares, Erik Hornes for 46,155 shares, Dagfinn Strømme for 289 shares, Mathias Uhlen for 613,950 shares and Braganza AS for 1,895,200 shares in NorDiag ASA at a subscription price of NOK 8,50 per share. The shares were paid for by the transfer of their shares in Genpoint AS to NorDiag ASA according to the share purchase agreement between the Genpoint-shareholders and NorDiag ASA.

On 16 March 2007 Novel Diagnostics ASA subscribed for 588,235 shares, START-fondet ASA subscribed for 176,471 shares and Biovekst AS subscribed for 411,765 shares in accordance with the said share purchase agreement at a subscription price of NOK 8,50 in the private placement conducted in relation to the acquisition of Genpoint AS.

Following the share issues the abovementioned owns the following shares in NorDiag ASA:

Barracuda Invest AS; 46 155 new shares. Total number of shares are 65 155.

START-fondet ASA; 3 155 982 new shares equal to total number of shares. This accounts for 8.5% of share capital and votes in the Company.
 
Biovekst AS; 2 166 607 new shares equal to total number of shares. This accounts for 5.8% of share capital and votes in the Company.

Anders Holmberg; 734 655 new shares equal to total number of shares.
 
Erik Hornes; 46 155 new shares equal to total number of shares.

Dagfinn Strømme; 289 new shares equal to total number of shares.

Mathias Uhlèn; 613 950 new shares equal to total number of shares.

Novel Diagnostics ASA; 588 235 new shares. Total number of shares are 3 845 660. This accounts for 10.4% of share capital and votes in the Company.

Braganza AS; 1 895 200 new shares equal to total number of shares. This accounts for 5.1% of share capital and votes in the Company. 

Barracuda Invest AS is owned by Mårten Wigstøl, who is CEO of NorDiag ASA. Hans Hekland is chairman of the board of Novel Diagnostics ASA and NorDiag ASA, J. Frode Vaksvik is CEO of START-fondet ASA and member of the board of NorDiag ASA, Jan Olav Steensland is member of the board of Biovekst AS and NorDiag ASA, Anders Holmberg is Director of Business Development in Magnetic Biosolutions AB (subsidiary of Genpoint AS), Erik Hornes is CEO and member of the board of Genpoint AS, Dagfinn Strømme is Sales- and Marketing Director of Genpoint AS and Mathias Uhlen is board member of NorDiag ASA.

Read the notice in Norwegian here